HHMI: Bitterness Remains

WASHINGTON—Behind Donald Fredrickson's forced resignation June 2 as president and lifetime trustee of the Howard Hughes Medical Institute lies a tale of budget overruns and unorthodox purchasing procedures that HHMI trustees and officials say stem from his wife's active and inappropriate role at the institute. "It's big and it's bad," said HHMI chairman George Thorn about the results of the six-month review conducted by the New York law firm of Paul, Weiss, Rifkind, Wharton & Garrison, abo

Written byRon Cowen
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

"It's big and it's bad," said HHMI chairman George Thorn about the results of the six-month review conducted by the New York law firm of Paul, Weiss, Rifkind, Wharton & Garrison, about which he declined to provide details. Thorn is serving as acting chief executive officer while a search continues for a new president.

Fredrickson, a former NIH director, has a sharply different view of the events that led to his departure from the $5 billion institute that he had headed since 1984. An investigation into "rumors" that his wife, Henrietta, had too large a role in HHMI activities soon mushroomed into brutal personal questioning that made it "impossible [for me] to go back," he said.

Fredrickson acknowledges that one item that came under scrutiny is a $2.5 million cost overrun in a $12.5 million project to renovate the Cloisters, a former convent on the NIH campus being converted into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies